LMR Partners LLP Makes New $1.54 Million Investment in BeiGene, Ltd. (NASDAQ:BGNE)

LMR Partners LLP acquired a new stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,838 shares of the company's stock, valued at approximately $1,535,000.

Several other large investors have also bought and sold shares of BGNE. Capital International Investors lifted its holdings in BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company's stock valued at $1,104,806,000 after acquiring an additional 727,556 shares during the last quarter. Baillie Gifford & Co. grew its position in BeiGene by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,705,756 shares of the company's stock worth $831,979,000 after buying an additional 23,807 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in BeiGene by 6.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company's stock worth $316,862,000 after buying an additional 117,905 shares during the last quarter. Capital International Inc. CA increased its holdings in shares of BeiGene by 6.0% in the first quarter. Capital International Inc. CA now owns 858,364 shares of the company's stock valued at $134,240,000 after buying an additional 48,615 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of BeiGene during the 2nd quarter valued at $54,412,000. Institutional investors own 48.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BGNE. TD Cowen lifted their target price on BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price target on BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 22nd. JMP Securities initiated coverage on shares of BeiGene in a research note on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price objective for the company. StockNews.com raised shares of BeiGene from a "hold" rating to a "buy" rating in a research report on Wednesday, November 13th. Finally, Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $247.07.

Insider Buying and Selling

In other BeiGene news, SVP Chan Henry Lee sold 1,202 shares of the business's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $237.10, for a total value of $284,994.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Oyler sold 6,175 shares of the firm's stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,070 shares of company stock worth $4,901,050. Insiders own 7.43% of the company's stock.

BeiGene Stock Up 0.0 %

BGNE stock traded up $0.08 during midday trading on Tuesday, reaching $187.77. The company had a trading volume of 180,925 shares, compared to its average volume of 265,343. The company has a 50 day moving average of $212.79 and a two-hundred day moving average of $182.59. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $248.16. The company has a market capitalization of $18.29 billion, a P/E ratio of -22.77 and a beta of 0.63.

BeiGene (NASDAQ:BGNE - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. During the same period in the previous year, the business posted $2.01 EPS. BeiGene's revenue for the quarter was up 28.2% on a year-over-year basis. On average, equities research analysts expect that BeiGene, Ltd. will post -5.57 earnings per share for the current fiscal year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.